Antiviral therapy may lower risk of liver cancer

Beijing: Antiviral therapy can reduce the risk of liver cancer in patients with chronic hepatitis B infection, researchers have found.

The licensed oral antiviral agent nucleos(t)ide (NUC) resulted in a reduced long term risk for liver cancer chronic hepatitis B patients, the findings showed.

"Our findings suggest that NUC use reduces the risk of liver cancer in chronic hepatitis B patients, particularly in younger patients with minimal liver damage," said Chun-Ying Wu from National Yang-Ming University in Taiwan.

This study analysed the risk of hepatocellular carcinoma, the most common form of liver cancer, in patients treated with several different agents.

The NUC-treated cohort had a significantly lower seven-year incidence of liver cancer compared with a control group.

Liver cancer among hepatitis B patients causes approximately 745,000 deaths worldwide each year.

The findings appeared in the journal Gastroenterology.

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link